A carregar...

Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer

A third of patients with triple negative breast cancer (TNBC) have relapsed disease within 2–5 years from initial diagnosis, leaving an unmet need for therapeutic targets. TNBC frequently harbors alterations of the PI3K/AKT/mTOR pathway, but single agent PI3K/AKT/mTOR inhibitors have not shown marke...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Yuan, Yuan, Wen, Wei, Yost, Susan E., Xing, Quanhua, Yan, Jin, Han, Ernest S., Mortimer, Joanne, Yim, John H.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6525251/
https://ncbi.nlm.nih.gov/pubmed/31101835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-43429-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!